ADGRL4 and ovarian cancer: Paradoxically, high ADGRL4/ELTD1 expression in patients treated with systemic anti-cancer treatment correlated with improved overall survival (head and neck squamous carcinoma, renal, colorectal and ovarian cancers)4.